SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-20-008616
Filing Date
2020-12-17
Accepted
2020-12-17 16:55:44
Documents
13
Period of Report
2020-12-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_121720.htm   iXBRL 8-K 25088
2 EXHIBIT 10.1 exh_101.htm EX-10.1 18704
  Complete submission text file 0001171843-20-008616.txt   222719

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bcrx-20201216.xsd EX-101.SCH 3162
4 XBRL LABEL FILE bcrx-20201216_lab.xml EX-101.LAB 34591
5 XBRL PRESENTATION FILE bcrx-20201216_pre.xml EX-101.PRE 22694
6 EXTRACTED XBRL INSTANCE DOCUMENT f8k_121720_htm.xml XML 3588
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 201396738
SIC: 2836 Biological Products, (No Diagnostic Substances)